Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Cholangiocarcinoma 2 Acrocephalosyndactylia 2 Urinary Bladder Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Melanoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 166 Nivolumab 111 Ipilimumab 93 Dacarbazine 44 trametinib 36 dabrafenib 34 Vemurafenib 33 binimetinib 23 atezolizumab 23 Temozolomide 21 cemiplimab 18 Paclitaxel 18 encorafenib 17 spartalizumab 16 cobimetinib 15 Carboplatin 14 talimogene laherparepvec 13 Cisplatin 13 Cyclophosphamide 12 lenvatinib 10 Pemetrexed 10 Gemcitabine 10 Docetaxel 10 durvalumab 9 Drug Therapy 9 Bevacizumab 9 tremelimumab 8 Injections 8 Albumin-Bound Paclitaxel 8 130-nm albumin-bound paclitaxel 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × infigratinib × Clear all

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡